EC
GBT

EcoR1 Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

EcoR1 Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-28,032
Closed -$445K – 38
2016
Q1 		$445K Buy
+28,032
New +$498K 0.16% 34

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

EcoR1 Capital's GBT Position: Q2 2016 in Review

EcoR1 Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2016, closing a stake of 28,032 shares — an estimated $445K sold.

EcoR1 Capital first reported a position in GBT in Q1 2016 and held it in 1 quarter. The position peaked at $445K in Q1 2016. 93 funds tracked by Wall St. Rank hold GBT as of Q2 2016.

  • EcoR1 Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • EcoR1 Capital sold 28,032 Global Blood Therapeutics, Inc. shares in Q2 2016, an estimated $445K.
  • EcoR1 Capital first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • EcoR1 Capital's Global Blood Therapeutics, Inc. position peaked at $445K in Q1 2016.
  • 93 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2016.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.